BOCA RATON, Fla.--(BUSINESS WIRE)--Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that its wholly-owned drug discovery subsidiary, ReceptoPharm, has published the positive results of its recent pain study in Toxicon, the official journal of the International Society on Toxinology. The study, which examined ReceptoPharm’s leading drug candidate for the treatment of pain, RPI-78, showed that the pain reducing effects of RPI-78 lasted four-times as long as morphine and without the negative side effects associated with opioid-based pain relievers.
